Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non-Small-Cell Lung Cancer (GALAXY-2).

Pillai, Rathi N

Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non-Small-Cell Lung Cancer (GALAXY-2). [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology 02 2020 - 613-622 p. digital

Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial

1527-7755

10.1200/JCO.19.00816 doi


Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Carcinoma, Non-Small-Cell Lung--drug therapy
Docetaxel--therapeutic use
Female
HSP90 Heat-Shock Proteins--antagonists & inhibitors
Humans
Lung Neoplasms--drug therapy
Male
Middle Aged
Progression-Free Survival
Salvage Therapy--methods
Treatment Outcome
Triazoles--therapeutic use